文献速递MDS 与骨髓增殖性肿瘤

组蛋白去甲基化酶JMJD2C是NFE2的新型靶基因,为JAK2V617F突变细胞存活所必需

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells.
PubMed 文献 · Leukemia · 2023-01-28

本研究探讨NFE2驱动骨髓增殖性肿瘤(MPN)向急性白血病转化的分子机制,发现组蛋白去甲基化酶JMJD2C是NFE2的新型靶基因。JMJD2C在MPN患者及NFE2转基因小鼠中表达升高,且JMJD2C缺失选择性损害JAK2V617F突变细胞的增殖。数据提示JMJD2C是MPN中有前景的药物靶点,并为进一步的临床前和临床研究提供了依据。

要点

  • JMJD2C是NFE2的新型靶基因,在MPN患者和NFE2转基因小鼠中表达升高。
  • JMJD2C缺失选择性损害JAK2V617F突变细胞的增殖。
  • JMJD2C可能是MPN中有前景的药物靶点。

核心结论

  • JMJD2C是NFE2的新型靶基因,其缺失选择性损害JAK2V617F突变细胞的增殖。
  • 数据提示JMJD2C是MPN中有前景的药物靶点,并为进一步的临床前和临床研究提供了依据。

研究设计与样本

  • 本研究为实验室研究,探讨NFE2驱动白血病转化的分子机制。

主要发现

  • JMJD2C在MPN患者及NFE2转基因小鼠中表达升高。
  • JMJD2C缺失选择性损害JAK2V617F突变细胞的增殖。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The transcription factor NFE2 is overexpressed in most patients with myeloproliferative neoplasms (MPN). Moreover, mutations in NFE2, found in a subset of MPN patients, strongly predispose for transformation to acute leukemia. Transgenic mice overexpressing NFE2 as well as mice harboring NFE2 mutations display an MPN phenotype and spontaneously develop leukemia. However, the molecular mechanisms effecting NFE2-driven leukemic transformation remain incompletely understood. Here we show that the pro-leukemic histone demethylase JMJD2C constitutes a novel NFE2 target gene. JMJD2C expression is elevated in MPN patients as well as in NFE2 transgenic mice. Moreover, we show that loss of JMJD2C selectively impairs proliferation of JAK2V617F mutated cells. Our data suggest that JMJD2C represents a promising drug target in MPN and provide a rationale for further investigation in preclinical and clinical settings.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Staehle AM, Peeken JC, Vladimirov G, et al. The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells. Leukemia. 2023. PMID: 36709354. doi:10.1038/s41375-023-01826-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。